Federal regulators shook up the booming weight loss drug marketplace when they announced Mounjaro and Zepbound to be no ...

There’s a war brewing over blockbuster weight loss medications — and patients are now getting caught in the crossfire.

The FDA decision will enable Antag Therapeutics to initiate the clinical development of its lead candidate drug, a ...

WW stock popped after announcing a new compounded semaglutide product to benefit from the current shortage of weight loss ...

PBMs are putting weight loss drugs, including Wegovy and Zepbound, on their national formularies, but coverage by plans is ...

After psychological side effects doomed the first generation of cannabinoid receptor 1–targeting drugs for weight loss, Novo ...

Newly released data shows that the U.S. may have reached peak obesity in 2020 — and the timing unsurprisingly coincides with ...

The FDA updated its database of drugs in shortage to remove tirzepatide, which had sat on that list – along with related ...

Authorizing Medicare to cover weight loss drugs would increase federal spending by about $35 billion from 2026 to 2034 ...

The group represents makers of compounded versions of drugs that benefit from shortages of branded FDA-approved medications like tirzepatide and Novo's (NVO) rival weight loss therapy, semaglutide.

Eli Lilly And Co. (NYSE:LLY) is ramping up its legal campaign against the compounding companies temporarily allowed to make ...

After nearly two years, federal regulators announced the shortage of the active ingredient in Mounjaro and Zepbound has been ...